Lessons from SENCOVAC : a prospective study evaluating the response to SARS-CoV-2 vaccination in the CKD spectrum
Quiroga, Borja (Hospital Universitario de la Princesa (Madrid))
Soler, María José (Hospital Universitari Vall d'Hebron)
Ortiz, Alberto (Universidad Autónoma de Madrid)
Sequera, Patricia de (Instituto de Investigación Carlos III)
Universitat Autònoma de Barcelona

Data:	2022
Resum:	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has negatively impacted on patients of the whole CKD spectrum, causing high rates of morbi-mortality. SARS-CoV-2 vaccines opened a new era, but patients with CKD (including kidney transplant, hemodialysis and peritoneal dialysis) were systematically excluded from pivotal clinical trials. The Spanish Society of Nephrology promoted the multicentric national SENCOVAC study aimed at assessing immunological responses after vaccination in patients with CKD. During the first year after vaccination, patients with non-dialysis CKD and those on hemodialysis and peritoneal dialysis presented good anti-Spike antibody responses to vaccination, especially after receiving the third and fourth doses. However, kidney transplant recipients presented suboptimal responses after any vaccination schedule (initial, third and fourth dose). Especially worrisome is the situation of a patients with a persistently negative humoral response that do not seroconvert after boosters. In this regard, monoclonal antibodies targeting SARS-CoV-2 have been approved for high-risk patients, although they may become obsolete as the viral genome evolves. The present report reviews the current status of SARS-CoV-2 vaccination in the CKD spectrum with emphasis on lessons learned from the SENCOVAC study. Predictors of humoral response, including vaccination schedules and types of vaccines, as well as the integration of vaccines, monoclonal antibodies and antiviral agents are discussed.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	SARS-CoV-2 ; COVID-19 ; CKD ; Hemodialysis ; Peritoneal dialysis ; Kidney transplant ; Anti-spike ; Humoral response ; Vaccines
Publicat a:	Nefrología (Madrid), december 2022, ISSN 1989-2284

DOI: 10.1016/j.nefro.2022.12.006
PMID: 36540904

13 p, 1.6 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats